메뉴 건너뛰기




Volumn 76, Issue 15, 2016, Pages 4504-4515

Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer

(31)  Oddo, Daniele a,b   Sennott, Erin M c   Barault, Ludovic a,b   Valtorta, Emanuele d   Arena, Sabrina a,b   Cassingena, Andrea d   Filiciotto, Genny a,b   Marzolla, Giulia a,b   Elez, Elena e   Van Geel, Robin M J M f   Bartolini, Alice b   Crisafulli, Giovanni b   Boscaro, Valentina g   Godfrey, Jason T c   Buscarino, Michela b   Cancelliere, Carlotta b   Linnebacher, Michael h   Corti, Giorgio b   Truini, Mauro d   Siravegna, Giulia a,b,i   more..


Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; B RAF KINASE; B RAF KINASE INHIBITOR; BINIMETINIB; CELL DNA; CETUXIMAB; DABRAFENIB; DNA; ENCORAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GENOMIC DNA; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SELUMETINIB; TRAMETINIB; VEMURAFENIB;

EID: 84982684991     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0396     Document Type: Article
Times cited : (94)

References (49)
  • 2
    • 84863922124 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of human colon and rectal cancer
    • The Cancer Genome Atlas Network
    • The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
    • (2012) Nature , vol.487 , pp. 330-337
  • 7
    • 84951810474 scopus 로고    scopus 로고
    • Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
    • Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015;33:4032-8.
    • (2015) J Clin Oncol , vol.33 , pp. 4032-4038
    • Kopetz, S.1    Desai, J.2    Chan, E.3    Hecht, J.R.4    O'Dwyer, P.J.5    Maru, D.6
  • 8
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.
    • (2012) Cancer Discov , vol.2 , pp. 227-235
    • Corcoran, R.B.1    Ebi, H.2    Turke, A.B.3    Coffee, E.M.4    Nishino, M.5    Cogdill, A.P.6
  • 9
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1    Sun, C.2    Huang, S.3    Di Nicolantonio, F.4    Salazar, R.5    Zecchin, D.6
  • 10
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013;19:657-67.
    • (2013) Clin Cancer Res , vol.19 , pp. 657-667
    • Mao, M.1    Tian, F.2    Mariadason, J.M.3    Tsao, C.C.4    Lemos, R.5    Dayyani, F.6
  • 11
    • 84923100781 scopus 로고    scopus 로고
    • Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC)
    • Bendell JC, Atreya CE, André T, Tabernero J, Gordon MS, Bernards R, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 32:5s, 2014 (suppl; abstr 3515).
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Bendell, J.C.1    Atreya, C.E.2    André, T.3    Tabernero, J.4    Gordon, M.S.5    Bernards, R.6
  • 12
    • 84919393400 scopus 로고    scopus 로고
    • Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer
    • Van Geel R, Elez E, Bendell JC, Faris JE, Lolkema MPJK, Eskens F, et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 3514).
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Van Geel, R.1    Elez, E.2    Bendell, J.C.3    Faris, J.E.4    Lolkema, M.P.J.K.5    Eskens, F.6
  • 13
    • 84925134597 scopus 로고    scopus 로고
    • Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer
    • Hong DS, Van Karlyle M, Fu S, Overman MJ, Piha-Paul SA, Kee BK, et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 3516).
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Hong, D.S.1    Van Karlyle, M.2    Fu, S.3    Overman, M.J.4    Piha-Paul, S.A.5    Kee, B.K.6
  • 14
    • 84951745408 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer
    • Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015;33:4023-31.
    • (2015) J Clin Oncol , vol.33 , pp. 4023-4031
    • Corcoran, R.B.1    Atreya, C.E.2    Falchook, G.S.3    Kwak, E.L.4    Ryan, D.P.5    Bendell, J.C.6
  • 15
    • 84925133542 scopus 로고    scopus 로고
    • VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC)
    • Tabernero J, Chan E, Baselga J, Blay JY, Chau I, Hyman DM, et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol 32:5s, 2014 (suppl; abstr 3518∧).
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Tabernero, J.1    Chan, E.2    Baselga, J.3    Blay, J.Y.4    Chau, I.5    Hyman, D.M.6
  • 16
    • 84961063545 scopus 로고    scopus 로고
    • A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer
    • Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs 2016;34:168-75.
    • (2016) Invest New Drugs , vol.34 , pp. 168-175
    • Deming, D.A.1    Cavalcante, L.L.2    Lubner, S.J.3    Mulkerin, D.L.4    LoConte, N.K.5    Eickhoff, J.C.6
  • 17
    • 84908431348 scopus 로고    scopus 로고
    • Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
    • Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-80.
    • (2014) Cancer Discov , vol.4 , pp. 1269-1280
    • Misale, S.1    Di Nicolantonio, F.2    Sartore-Bianchi, A.3    Siena, S.4    Bardelli, A.5
  • 18
    • 84921270388 scopus 로고    scopus 로고
    • Targeting RAS-ERK signalling in cancer: Promises and challenges
    • Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 2014;13:928-42.
    • (2014) Nat Rev Drug Discov , vol.13 , pp. 928-942
    • Samatar, A.A.1    Poulikakos, P.I.2
  • 19
    • 84896078397 scopus 로고    scopus 로고
    • Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
    • Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014;6:224ra26.
    • (2014) Sci Transl Med , vol.6
    • Misale, S.1    Arena, S.2    Lamba, S.3    Siravegna, G.4    Lallo, A.5    Hobor, S.6
  • 21
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
    • (2007) Science , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3    Song, Y.4    Hyland, C.5    Park, J.O.6
  • 22
    • 77249105997 scopus 로고    scopus 로고
    • Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro
    • Roig AI, Eskiocak U, Hight SK, Kim SB, Delgado O, Souza RF, et al. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology 2010;138:1012-21 e1-5.
    • (2010) Gastroenterology , vol.138
    • Roig, A.I.1    Eskiocak, U.2    Hight, S.K.3    Kim, S.B.4    Delgado, O.5    Souza, R.F.6
  • 23
    • 84936748494 scopus 로고    scopus 로고
    • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
    • Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015;21:795-801.
    • (2015) Nat Med , vol.21 , pp. 795-801
    • Siravegna, G.1    Mussolin, B.2    Buscarino, M.3    Corti, G.4    Cassingena, A.5    Crisafulli, G.6
  • 24
    • 0034278156 scopus 로고    scopus 로고
    • Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy
    • Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000;2:308-16.
    • (2000) J Gene Med , vol.2 , pp. 308-316
    • Vigna, E.1    Naldini, L.2
  • 25
    • 84932606172 scopus 로고    scopus 로고
    • Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
    • Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015;21:2157-66.
    • (2015) Clin Cancer Res , vol.21 , pp. 2157-2166
    • Arena, S.1    Bellosillo, B.2    Siravegna, G.3    Martinez, A.4    Canadas, I.5    Lazzari, L.6
  • 26
    • 83455254767 scopus 로고    scopus 로고
    • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    • Poulikakos PI, Persaud Y, Janakiraman M, Kong XJ, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
    • (2011) Nature , vol.480 , pp. 387-390
    • Poulikakos, P.I.1    Persaud, Y.2    Janakiraman, M.3    Kong, X.J.4    Ng, C.5    Moriceau, G.6
  • 27
    • 84880254869 scopus 로고    scopus 로고
    • Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
    • Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50.
    • (2013) Cancer Discov , vol.3 , pp. 742-750
    • Morris, E.J.1    Jha, S.2    Restaino, C.R.3    Dayananth, P.4    Zhu, H.5    Cooper, A.6
  • 29
    • 78650008177 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
    • Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
    • (2010) Cancer Cell , vol.18 , pp. 683-695
    • Villanueva, J.1    Vultur, A.2    Lee, J.T.3    Somasundaram, R.4    Fukunaga-Kalabis, M.5    Cipolla, A.K.6
  • 30
    • 84933040790 scopus 로고    scopus 로고
    • Clinical acquired resistance to RAF inhibitor combinations in braf-mutant colorectal cancer through MAPK pathway alterations
    • Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in braf-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015;5:358-67.
    • (2015) Cancer Discov , vol.5 , pp. 358-367
    • Ahronian, L.G.1    Sennott, E.M.2    Van Allen, E.M.3    Wagle, N.4    Kwak, E.L.5    Faris, J.E.6
  • 31
    • 79953240219 scopus 로고    scopus 로고
    • Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells
    • Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011;4:ra17.
    • (2011) Sci Signal , vol.4 , pp. ra17
    • Little, A.S.1    Balmanno, K.2    Sale, M.J.3    Newman, S.4    Dry, J.R.5    Hampson, M.6
  • 32
    • 78649436372 scopus 로고    scopus 로고
    • BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
    • Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3:ra84.
    • (2010) Sci Signal , vol.3 , pp. ra84
    • Corcoran, R.B.1    Dias-Santagata, D.2    Bergethon, K.3    Iafrate, A.J.4    Settleman, J.5    Engelman, J.A.6
  • 33
    • 84859183431 scopus 로고    scopus 로고
    • Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
    • Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724.
    • (2012) Nat Commun , vol.3 , pp. 724
    • Shi, H.1    Moriceau, G.2    Kong, X.3    Lee, M.K.4    Lee, H.5    Koya, R.C.6
  • 35
    • 84897531613 scopus 로고    scopus 로고
    • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
    • Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014;508:118-22.
    • (2014) Nature , vol.508 , pp. 118-122
    • Sun, C.1    Wang, L.2    Huang, S.3    Heynen, G.J.4    Prahallad, A.5    Robert, C.6
  • 36
    • 84911922237 scopus 로고    scopus 로고
    • Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor
    • Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014;32:3697-704.
    • (2014) J Clin Oncol , vol.32 , pp. 3697-3704
    • Johnson, D.B.1    Flaherty, K.T.2    Weber, J.S.3    Infante, J.R.4    Kim, K.B.5    Kefford, R.F.6
  • 37
    • 84925205335 scopus 로고    scopus 로고
    • Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models
    • Liu L, Shi H, Bleam MR, Zhang V, Zou J, Jing J, et al. Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models. J Clin Oncol 32:5s, 2014 (suppl; abstr 3513).
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Liu, L.1    Shi, H.2    Bleam, M.R.3    Zhang, V.4    Zou, J.5    Jing, J.6
  • 38
    • 84899470984 scopus 로고    scopus 로고
    • Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
    • Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 2014;8:544-54.
    • (2014) Mol Oncol , vol.8 , pp. 544-554
    • Carlino, M.S.1    Todd, J.R.2    Gowrishankar, K.3    Mijatov, B.4    Pupo, G.M.5    Fung, C.6
  • 40
    • 84984969720 scopus 로고    scopus 로고
    • LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer
    • Elez E, Schellens J, van Geel R, Bendell J, Spreafico A, Schuler M, et al. LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer. Ann Onc 2015;26:iv120.
    • (2015) Ann Onc , vol.26 , pp. iv120
    • Elez, E.1    Schellens, J.2    Van Geel, R.3    Bendell, J.4    Spreafico, A.5    Schuler, M.6
  • 42
    • 79952463028 scopus 로고    scopus 로고
    • Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation
    • Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011;128:2075-84.
    • (2011) Int J Cancer , vol.128 , pp. 2075-2084
    • Tie, J.1    Gibbs, P.2    Lipton, L.3    Christie, M.4    Jorissen, R.N.5    Burgess, A.W.6
  • 44
    • 84960804625 scopus 로고    scopus 로고
    • Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF
    • Cisowski J, Sayin VI, Liu M, Karlsson C, Bergo MO. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Oncogene 2016;35:1328-33.
    • (2016) Oncogene , vol.35 , pp. 1328-1333
    • Cisowski, J.1    Sayin, V.I.2    Liu, M.3    Karlsson, C.4    Bergo, M.O.5
  • 47
    • 84922875490 scopus 로고    scopus 로고
    • Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction
    • Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 2015;27:240-56.
    • (2015) Cancer Cell , vol.27 , pp. 240-256
    • Moriceau, G.1    Hugo, W.2    Hong, A.3    Shi, H.4    Kong, X.5    Yu, C.C.6
  • 48
    • 84968415547 scopus 로고    scopus 로고
    • LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
    • Van Cutsem E, Atreya C, André T, Bendell J, Schellens J, Gordon M, et al. LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Onc 2015;26:iv119.
    • (2015) Ann Onc , vol.26 , pp. iv119
    • Van Cutsem, E.1    Atreya, C.2    André, T.3    Bendell, J.4    Schellens, J.5    Gordon, M.6
  • 49
    • 84916899372 scopus 로고    scopus 로고
    • ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors
    • Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res 2014;74:7079-89.
    • (2014) Cancer Res , vol.74 , pp. 7079-7089
    • Goetz, E.M.1    Ghandi, M.2    Treacy, D.J.3    Wagle, N.4    Garraway, L.A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.